Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $42.75 Average Target Price from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been given an average rating of “Moderate Buy” by the seven analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $42.75.

A number of equities analysts have recently commented on ASMB shares. Guggenheim reaffirmed a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a report on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Monday, April 20th. Finally, Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $22.90 on Monday. The firm’s fifty day simple moving average is $28.19 and its 200-day simple moving average is $30.01. The stock has a market capitalization of $363.88 million, a price-to-earnings ratio of -208.16 and a beta of 1.07. Assembly Biosciences has a 12 month low of $15.54 and a 12 month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. The business had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. Analysts anticipate that Assembly Biosciences will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its stake in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. Seven Fleet Capital Management LP acquired a new position in Assembly Biosciences in the 4th quarter valued at $147,000. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences in the 4th quarter valued at $228,000. Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences in the 4th quarter valued at $251,000. Finally, Engineers Gate Manager LP acquired a new position in Assembly Biosciences in the 4th quarter valued at $353,000. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.